Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Not yet recruiting 3Recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 2Genitourinary 1Breast 1

Conditions

Sarcoma 2Triple Negative Breast Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1

Interventions

Specimen Handling 278Magnetic Resonance Spectroscopy 233pembrolizumab 227Carboplatin 187Cisplatin 153Biopsy 148Cyclophosphamide 143Paclitaxel 133Nivolumab 122Gemcitabine 113Bevacizumab 104Radiotherapy 92Dexamethasone 86Pemetrexed 83fludarabine 77Fluorouracil 76Docetaxel 75Doxorubicin 74atezolizumab 71Radiation 71Leucovorin 70Rituximab 67Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 60Vincristine 56Cetuximab 56Lenalidomide 54Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × anlotinib × 30 days × Clear all
NCT07616141 2026-06-01

NAET4-SNACC

Eye & ENT Hospital of Fudan University

Phase 2 Not yet recruiting
76 enrolled

Carcinoma, Adenoid Cystic

NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07612098 2026-05-28

SPARE-04

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
274 enrolled
Sarcoma

Sarcoma

NCT07602101 2026-05-22

Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma

RenJi Hospital

Phase 2 Not yet recruiting
33 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT05301764 2026-05-20

A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma

Lyvgen Biopharma Holdings Limited

Phase 1/2 Completed
39 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡